SCHEMBL1486496

SCHEMBL1486496

CCOC(=O)c1cc(O)ccc1-n1nnnc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 0.54
▸ CA1 P00915 4/20 0.54
▸ CA2 P00918 4/20 0.54
▸ CA7 P43166 4/20 0.54
▸ CA9 Q16790 4/20 0.54
▸ CA14 Q9ULX7 4/20 0.54
▸ MIF P14174 1/20 0.44
▸ PFKFB3 Q16875 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ ROCK2 O75116 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ PRKACA P17612 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ CSNK1D P48730 1/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ CDK5 Q00535 1/20 0.41
▸ PRKCD Q05655 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1486749 0.83 KDM4E (0.40) MAPK1TSHRLMNAUSP2
SCHEMBL6099859 0.83 TSHR (0.54) MAPK1TSHRLMNAOPRM1
SCHEMBL3353271 0.77 RAB9A (0.41) MAPK1CSNK1DTSHRLMNA
SCHEMBL10449048 0.72 CA12 (0.77) CA12CA1CA2CA7CA9
SCHEMBL2390291 0.72 ESR1 (0.40) ESR1ESR2LMNA
SCHEMBL3353715 0.72 OPRK1 (0.47) TSHRUSP2
SCHEMBL5316745 0.71 CA12 (0.70) CA12CA1CA2CA7CA9
SCHEMBL550228 0.71 CA12 (0.74) CA12CA1CA2CA7CA9
SCHEMBL29457603 0.71 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL39259 0.71 CA12 (1.00) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658076-B1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2013-03-06 — — EP disclosed
US-8263594-B2 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-09-11 — — US disclosed
US-20110144099-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2011-06-16 — — US disclosed
US-7897597-B2 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 — — US disclosed
US-20090018122-A1 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2009-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018122-A1 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines IL2, IFNG, IRF3 CA12 4807/4885CA1 4819/4885CA2 4665/4885
US-20110144099-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 CA12 4790/4885CA1 4769/4885CA2 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback